Recent Updates
Recently added Catalysts

PF-07275315

Phase 2

Asthma | Small molecule | Respiratory |Pfizer, Inc.|Last Updated: May 4, 2026

Target and mechanism

Molecular targetITGB6
Target classInhibitor
ModalitySmall molecule
ChEMBLCHEMBL5314878

Also known as sigvotatug vedotin, Sigvotatug Vedotin, PF-07275315 dose 1

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment252

FDA Designations

No designations recorded

Clinical trial landscape

PF-07275315 · 4 trials · 4 indications

Phase 2 2Phase 1 2
NCT06977581A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaAsthma
RECRUITING252 Analytics
NCT05995964A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisAtopic Dermatitis
RECRUITING340 Analytics
PHASE2RECRUITING
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
NCT06977581252
Unlock trial analytics
PHASE2RECRUITING
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
NCT05995964340
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12
Week 12

FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.

Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and AEs/SAEs leading to treatment discontinuation
Baseline through Week 24

Incidence of treatment-emergent AEs, treatment-emergent SAEs, and treatment-emergent AEs/SAEs leading to treatment discontinuation

Clinically significant, treatment-related laboratory abnormalities
Baseline through Week 24

Incidence of clinically significant changes in laboratory tests

Clinically significant, treatment-related abnormalities in vital signs
Baseline through Week 24

Incidence of clinically significant changes in vital signs

Clinically significant, treatment-related electrocardiogram (ECG) abnormalities
Baseline through Week 24

Incidence of clinically significant changes in ECG

The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.
Week 16

EASI75 (≥75% improvement from baseline) at Week 16

Maximum Observed Plasma Concentration (Cmax)
Up to Day 181
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Up to Day 181
area under the concentration-time curve from time 0 to 336 hours (AUC336)
Up to Day 181
Area under the concentration-time curve from time 0 to infinity (AUCinf)
Up to Day 181
Area under the concentration-time curve from 0 to time of last measurable concentration (AUClast)
Up to Day 181
Terminal phase half-life (t½)
Up to Day 181
Incidence of treatment-emergent adverse events (TEAEs)
Up to Day 181
Incidence of treatment-emergent serious adverse events (SAEs)
Up to Day 181
Incidence of abnormal and clinically relevant changes in vital signs
Up to Day 181
Incidence of abnormal and clinically relevant changes in electrocardiogram
Up to Day 181
Incidence of abnormal and clinically relevant changes in laboratory assessments
Up to Day 181
Number of participants with Adverse Events (AEs)
Baseline through study completion, approximately 561 days

Incidence and severity of AEs

Number of participants with clinically meaningful change from baseline in laboratory Tests Results
Baseline through study completion, approximately 561 days

Number of Participants With Change From Baseline in Laboratory Tests Results

Number of participants with clinically meaningful change from baseline in vital signs
Baseline through study completion, approximately 561 days

Number of participants with change from baseline in vital signs

Number of participants with Serious AEs (SAEs)
Baseline through study completion, approximately 561 days

Incidence and severity of SAEs

Number of participants with clinically meaningful change from baseline in ECG parameters
Baseline through study completion, approximately 561 days

number of participants with change from baseline in ECG parameters

Secondary Endpoints

Change from baseline in pre-bronchodilator Percent (%) Predicted FEV1 at Week 12
Week 12
Change from baseline in pre-bronchodilator FEV1 at all time points
Baseline through Week 24
Change from baseline in pre-bronchodilator % Predicted FEV1 at all time points
Baseline through Week 24
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Treatment Arm AEXPERIMENTALPF-07275315
Treatment Arm BEXPERIMENTALPF-07275315
Treatment Arm CEXPERIMENTALPF-07275315
Treatment Arm DPLACEBO_COMPARATORPlacebo
Stage 1_PF-07275315EXPERIMENTALStage 1 PF-07275315 Injections over 12 weeks
Stage 1_PF-07264660EXPERIMENTALStage 1 PF-07264660 Injections over 12 weeks
Stage 1_PlaceboEXPERIMENTALStage 1 Placebo Injections over 12 weeks
Stage 2_PF-07275315 _Dose AEXPERIMENTALStage 2 PF-07275315 Injections over 12 weeks.
Stage 2_PF-07275315 _Dose BEXPERIMENTALStage 2 PF-07275315 Injections over 12 weeks.
Stage 2_PF-07275315 _Dose CEXPERIMENTALStage 2 PF-07275315 Injections over 12 weeks.
Stage 2_PF-07275315 _Dose DEXPERIMENTALStage 2 PF-07275315 or PF-07264660 Injections over 12 weeks.
Stage 2_PlaceboEXPERIMENTALStage 2 Placebo Injections over 12 weeks.
Stage 3_Placebo+PF-07275315_Dose AEXPERIMENTALStage 3 Placebo Injections for 16 weeks followed by PF-07275315 Injections for 16 weeks.
Stage 3_PF-07275315_Dose BEXPERIMENTALStage 3 PF-07275315 Injections for 32 weeks.
Stage 4_PF-07264660_Dose AEXPERIMENTALStage 4 PF-07264660 Injections for 12 weeks
Stage 4_PF-07264660_Dose BEXPERIMENTALStage 4 PF-07264660 Injections for 12 weeks
Stage 4_PF-07264660_Dose CEXPERIMENTALStage 4 PF-07264660 Injections for 12 weeks
Stage 4_PlaceboEXPERIMENTALStage 2 Placebo Injections for 12 weeks
PF-07275315EXPERIMENTALParticipants will receive a single dose of PF-07275315 via IV infusion
PlaceboPLACEBO_COMPARATORParticipants will receive a single dose of placebo via IV infusion
ActiveEXPERIMENTALPF-07275315

Interventions

NameTypeDescription
PF-07275315DRUGsubcutaneous injection
PlaceboOTHERsubcutaneous injection
PF-07264660DRUGsubcutaneous injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites132

Inclusion Criteria: Must meet the following asthma criteria: 1. History of persistent, moderate-to-severe asthma for at least 12 months prior to screening. 2. Must have experienced at least 1 asthma exacerbation requiring treatment with systemic steroids (oral or parenteral) for 3 days or more wit...

Countries:United StatesArgentinaBelgiumBulgariaChinaCzechiaHungaryItalyJapanPolandSouth AfricaSouth KoreaSpainTaiwanUnited KingdomAustraliaCanadaGermany
Unlock Eligibility Criteria

Competitive Landscape -Asthma 76 trials

CompanyTickerTrialsLead PhaseDrugs
Teva Pharmaceutical Industries Limited Sponsored ADRTEVA4PHASE3Fp/ABS, ABS
Novartis AG Sponsored ADRNVS5PHASE3QVM149, Salmeterol Xinafoate/ Fluticasone Propionate
GSK plc Sponsored ADRGSK5PHASE3FF/UMEC/VI
Sanofi SA Sponsored ADRSNY7PHASE3Dupilumab
AstraZeneca PLCAZN27PHASE3Benralizumab
Generate Biomedicines, Inc.GENB3PHASE3GB-0895
Eli Lilly and CompanyLLY1PHASE2Brenipatide
Incyte CorporationINCY1PHASE2povorcitinib, ICS-LABA
Pfizer Inc.PFE1PHASE2PF-07275315
Kymera Therapeutics, Inc.KYMR1PHASE2KT-621
Arrowhead Pharmaceuticals, Inc.ARWR1PHASE2ARO-RAGE
Upstream Bio, Inc.UPB1PHASE2Verekitug
Sunshine Biopharma IncorporatedSBFM2PHASE3610
Amgen Inc.AMGN1PHASE1AMG 691
Apogee Therapeutics, Inc.APGE1PHASE1APG777
Celldex Therapeutics, Inc.CLDX1PHASE1CDX-622
Unlock Competitive Intelligence

Frequently asked questions about PF-07275315

What is PF-07275315 used for?

PF-07275315, also known as sigvotatug vedotin, is an investigational small molecule being studied for moderate to severe atopic dermatitis, moderate to severe chronic obstructive pulmonary disease, asthma, and in healthy volunteers. It is in Phase 2 clinical development for these conditions.

What does PF-07275315 target?

PF-07275315 targets ITGB6, which is a subunit of integrin proteins. It acts as an inhibitor of this target. The drug is being evaluated for its potential role in treating inflammatory and respiratory conditions.

Who makes PF-07275315?

PF-07275315 is being developed by Pfizer, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various patient populations.

What phase is PF-07275315 in?

PF-07275315 is currently in Phase 2 clinical trials. It is an investigational drug and has not been approved by regulatory authorities. Studies are ongoing to assess its effects in conditions like atopic dermatitis and asthma.

What clinical trials is PF-07275315 in?

PF-07275315 is being studied in several clinical trials. NCT05995964 is a Phase 2 study in moderate to severe atopic dermatitis. NCT06977581 is a Phase 2 study in moderate-to-severe asthma. NCT04756531 was a Phase 1 study in healthy participants.

Is PF-07275315 the same as sigvotatug vedotin?

Yes, PF-07275315 is also known as sigvotatug vedotin. These names refer to the same investigational drug being developed by Pfizer. It is also referred to as PF-07275315 dose 1 in some contexts.